Rozanolixizumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Rozanolixizumab
DrugBank Accession Number
DB14919
Background

Rozanolixizumab is under investigation in clinical trial NCT03861481 (A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy).

Type
Biotech
Groups
Investigational
Synonyms
  • Rozanolixizumab

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with Rozanolixizumab.
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Rozanolixizumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Rozanolixizumab.
Adenovirus type 7 vaccine liveThe risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Rozanolixizumab.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Rozanolixizumab.
AlefaceptThe risk or severity of adverse effects can be increased when Alefacept is combined with Rozanolixizumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Rozanolixizumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Rozanolixizumab.
AltretamineThe risk or severity of adverse effects can be increased when Altretamine is combined with Rozanolixizumab.
AmsacrineThe risk or severity of adverse effects can be increased when Amsacrine is combined with Rozanolixizumab.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
P7186074QC
CAS number
1584645-37-3

References

General References
Not Available
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Enrolling by InvitationTreatmentGeneralized Myasthenia Gravis2
3Enrolling by InvitationTreatmentPrimary Immune Thrombocytopenia1
3RecruitingTreatmentGeneralized Myasthenia Gravis1
3RecruitingTreatmentPrimary Immune Thrombocytopenia2
2CompletedTreatmentChronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)1
2CompletedTreatmentMyasthenia Gravis1
2Enrolling by InvitationTreatmentChronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)1
1CompletedBasic ScienceHealthy-volunteers1
1Not Yet RecruitingBasic ScienceHealthy Study Participants1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on May 20, 2019 14:35 / Updated on February 21, 2021 18:55